Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.4K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.4K
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.1K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.1K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.4K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.4K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

959
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
959
Principles of Disease Surveillance01:26

Principles of Disease Surveillance

554
Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
554

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systematic review of outcome measures in facioscapulohumeral dystrophy (FSHD): validated, usable, and feasible tools for assessing function, performance, and strength.

Neuromuscular disorders : NMD·2026
Same author

Current biomarker development in myotonic dystrophies.

Journal of neurology·2026
Same author

Inflammation reprograms fibro-adipogenic progenitors to sustain immunopathogenic niches in myositis.

Cell death & disease·2026
Same author

Meningococcal prophylaxis in neurological diseases treated with complement inhibitors: an expert consensus for Germany, Austria, and Switzerland.

Therapeutic advances in neurological disorders·2026
Same author

Multicentric prognostic observational study on biomarker profile in immunotherapy-naïve patients with highly active generalized myasthenia gravis (PROGNO-MG): a study protocol.

Neurological research and practice·2026
Same author

Longitudinal Psychometric Properties of the Myotonic Dystrophy Health Index in a Large Multicenter Cohort of People Living With Myotonic Dystrophy Type 1.

Muscle & nerve·2026

Related Experiment Video

Updated: Feb 6, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

16.0K

Myotonic Dystrophy-A Progeroid Disease?

Peter Meinke1, Stefan Hintze1, Sarah Limmer1

  • 1Friedrich-Baur-Institute at the Department of Neurology, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.

Frontiers in Neurology
|August 25, 2018
PubMed
Summary
This summary is machine-generated.

Myotonic dystrophies (DM) exhibit accelerated aging features, suggesting a progeroid disorder. Cellular and clinical analyses reveal similarities to nuclear envelope-related progeroid syndromes, supporting DM as a segmental progeroid condition.

Keywords:
DNA repairmyotonic dystrophynuclear envelopepremature agingsegmental progeroid disorder

More Related Videos

A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy
05:54

A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy

Published on: December 29, 2017

10.5K
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.9K

Related Experiment Videos

Last Updated: Feb 6, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

16.0K
A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy
05:54

A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy

Published on: December 29, 2017

10.5K
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.9K

Area of Science:

  • Genetics and Molecular Biology
  • Aging Research
  • Neurology

Background:

  • Myotonic dystrophies (DM) are genetic disorders characterized by repeat expansions in specific genes.
  • Patients often display multisystemic involvement resembling accelerated aging, including cataracts, muscle weakness, and cardiac issues.
  • These aging phenotypes suggest DM might be a segmental progeroid disease.

Purpose of the Study:

  • To investigate the hypothesis that myotonic dystrophies are segmental progeroid disorders.
  • To identify molecular causes for the accelerated aging appearance in DM patients.
  • To compare clinical and cellular features of DM with known progeroid syndromes.

Main Methods:

  • Clinical feature comparison between DM patients and typical segmental progeroid disorders.
  • Cellular-level analysis using primary DM and control cell lines.
  • Investigation of molecular overlaps with classical progeroid disorders.

Main Results:

  • DM clinical features share similarities with segmental progeroid disorders linked to DNA repair and nuclear envelope proteins.
  • Cellular analysis revealed significant overlaps between DM and progeroid syndromes associated with the nuclear envelope.
  • The study identified molecular similarities at the cellular level.

Conclusions:

  • Myotonic dystrophies can be classified as a segmental progeroid disorder based on clinical and molecular evidence.
  • The accelerated aging phenotype in DM is linked to molecular pathways similar to those in nuclear envelope progeroid syndromes.
  • This classification provides a new perspective on the pathophysiology of myotonic dystrophies.